首页> 外文OA文献 >Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer.
【2h】

Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer.

机译:评估药剂师主导的药物评估,用于确定患有癌症的门诊老年人的多种药物的流行和相关性以及可能不适当的药物使用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PURPOSE: The use of multiple and/or inappropriate medications in seniors is a significant public health problem, and cancer treatment escalates its prevalence and complexity. Existing studies are limited by patient self-report and medical record extraction compared with a pharmacist-led comprehensive medication assessment.PATIENTS AND METHODS: We retrospectively examined medication use in ambulatory senior adults with cancer to determine the prevalence of polypharmacy (PP) and potentially inappropriate medication (PIM) use and associated factors. PP was defined as concurrent use of five or more and less than 10 medications, and excessive polypharmacy (EPP) was defined as 10 or more medications. PIMs were categorized by 2012 Beers Criteria, Screening Tool of Older Person\u27s Prescriptions (STOPP), and the Healthcare Effectiveness Data and Information Set (HEDIS).RESULTS: A total of 248 patients received a geriatric oncology assessment between January 2011 and June 2013 (mean age was 79.9 years, 64% were women, 74% were white, and 87% had solid tumors). Only 234 patients (evaluated by pharmacists) were included in the final analysis. Mean number of medications used was 9.23. The prevalence of PP, EPP, and PIM use was 41% (n = 96), 43% (n = 101), and 51% (n = 119), respectively. 2012 Beers, STOPP, and HEDIS criteria classified 173 occurrences of PIMs, which were present in 40%, 38%, and 21% of patients, respectively. Associations with PIM use were PP (P \u3c .001) and increased comorbidities (P = .005).CONCLUSION: A pharmacist-led comprehensive medication assessment demonstrated a high prevalence of PP, EPP, and PIM use. Medication assessments that integrate both 2012 Beers and STOPP criteria and consider cancer diagnosis, prognosis, and cancer-related therapy are needed to optimize medication use in this population.
机译:目的:在老年人中使用多种和/或不合适的药物是一个重大的公共卫生问题,癌症治疗使其患病率和复杂性上升。与药剂师主导的综合药物评估相比,现有研究受到患者自我报告和病历提取的限制。患者和方法:我们回顾性检查了非门诊老年癌症患者的药物使用情况,以确定多药(PP)的患病率和潜在的不适当之处药物(PIM)使用及相关因素。 PP被定义为同时使用五种或更多且少于十种药物,过量的多药店(EPP)被定义为十种或更多药物。根据2012年比尔斯啤酒标准,老年人处方筛选工具(STOPP)和医疗保健有效性数据和信息集(HEDIS)对PIM进行了分类。结果:2011年1月至2013年6月,共有248例患者接受了老年肿瘤学评估。 (平均年龄为79.9岁,女性为64%,白人为74%,实体瘤为87%)。最终分析中仅包括234名患者(由药剂师评估)。使用的平均药物数为9.23。 PP,EPP和PIM的使用率分别为41%(n = 96),43%(n = 101)和51%(n = 119)。 2012年Beers,STOPP和HEDIS标准对173次PIM发生进行了分类,分别在40%,38%和21%的患者中出现。与PIM的使用相关的是PP(P <0.001)和合并症(P = .005)。结论:药剂师主导的综合药物评估显示PP,EPP和PIM的使用率很高。需要结合2012 Beers和STOPP标准的药物评估,并考虑癌症的诊断,预后和与癌症相关的疗法,以优化该人群的药物使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号